Jared Barsky
Examiner (ID: 13656, Phone: (571)272-2795 , Office: P/1628 )
Most Active Art Unit | 1628 |
Art Unit(s) | 1628 |
Total Applications | 964 |
Issued Applications | 443 |
Pending Applications | 93 |
Abandoned Applications | 428 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 14072351
[patent_doc_number] => 20190085063
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-21
[patent_title] => Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer
[patent_app_type] => utility
[patent_app_number] => 16/014133
[patent_app_country] => US
[patent_app_date] => 2018-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27866
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16014133
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/014133 | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer | Jun 20, 2018 | Issued |
Array
(
[id] => 13456095
[patent_doc_number] => 20180279590
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-04
[patent_title] => Nucleic Acid Construct Comprising a P16 Promoter Controlling Expression of a Transgene that Causes Apoptosis in Senescent Cells
[patent_app_type] => utility
[patent_app_number] => 16/008974
[patent_app_country] => US
[patent_app_date] => 2018-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7567
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16008974
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/008974 | Nucleic Acid Construct Comprising a P16 Promoter Controlling Expression of a Transgene that Causes Apoptosis in Senescent Cells | Jun 13, 2018 | Abandoned |
Array
(
[id] => 15067135
[patent_doc_number] => 10463029
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2019-11-05
[patent_title] => Rodent model of steel syndrome
[patent_app_type] => utility
[patent_app_number] => 16/002233
[patent_app_country] => US
[patent_app_date] => 2018-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 6291
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16002233
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/002233 | Rodent model of steel syndrome | Jun 6, 2018 | Issued |
Array
(
[id] => 17904335
[patent_doc_number] => 11458168
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-04
[patent_title] => NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
[patent_app_type] => utility
[patent_app_number] => 15/987724
[patent_app_country] => US
[patent_app_date] => 2018-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 34
[patent_figures_cnt] => 34
[patent_no_of_words] => 17029
[patent_no_of_claims] => 35
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 111
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15987724
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/987724 | NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same | May 22, 2018 | Issued |
Array
(
[id] => 14067551
[patent_doc_number] => 20190082663
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-21
[patent_title] => Genetically Modified Non-Human Animals And Methods Of Use Thereof
[patent_app_type] => utility
[patent_app_number] => 15/980602
[patent_app_country] => US
[patent_app_date] => 2018-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17790
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15980602
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/980602 | Genetically modified non-human animals and methods of use thereof | May 14, 2018 | Issued |
Array
(
[id] => 13462437
[patent_doc_number] => 20180282761
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-04
[patent_title] => Chimaeric Surrogate Light Chains (SLC) Comprising Human VpreB
[patent_app_type] => utility
[patent_app_number] => 15/973376
[patent_app_country] => US
[patent_app_date] => 2018-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29244
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -76
[patent_words_short_claim] => 229
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15973376
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/973376 | Chimaeric Surrogate Light Chains (SLC) Comprising Human VpreB | May 6, 2018 | Pending |
Array
(
[id] => 15616099
[patent_doc_number] => 20200078454
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-12
[patent_title] => Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Cancer in a HLA-A*0201-Positive Patient Having a Non-Immunogenic Tumor Expressing Tert
[patent_app_type] => utility
[patent_app_number] => 16/611153
[patent_app_country] => US
[patent_app_date] => 2018-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7553
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611153
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/611153 | Use of a vaccine targeting a cryptic tert epitope, for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing tert | May 3, 2018 | Issued |
Array
(
[id] => 13386523
[patent_doc_number] => 20180244803
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-30
[patent_title] => Vivo Method for Generating Diversity in a Protein Scaffold
[patent_app_type] => utility
[patent_app_number] => 15/967271
[patent_app_country] => US
[patent_app_date] => 2018-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8700
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15967271
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/967271 | In vivo method for generating diversity in a protein scaffold | Apr 29, 2018 | Issued |
Array
(
[id] => 14419029
[patent_doc_number] => 10314298
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-06-11
[patent_title] => Humanized IL-7 rodents
[patent_app_type] => utility
[patent_app_number] => 15/960642
[patent_app_country] => US
[patent_app_date] => 2018-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 7977
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15960642
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/960642 | Humanized IL-7 rodents | Apr 23, 2018 | Issued |
Array
(
[id] => 17741394
[patent_doc_number] => 11389439
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-19
[patent_title] => Treatment and prevention of ocular neurodegenerative disorder
[patent_app_type] => utility
[patent_app_number] => 15/959379
[patent_app_country] => US
[patent_app_date] => 2018-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 73
[patent_no_of_words] => 23658
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15959379
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/959379 | Treatment and prevention of ocular neurodegenerative disorder | Apr 22, 2018 | Issued |
Array
(
[id] => 13372523
[patent_doc_number] => 20180237802
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-23
[patent_title] => PROTEIN HAVING NUCLEASE ACTIVITY, FUSION PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/960364
[patent_app_country] => US
[patent_app_date] => 2018-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23771
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 174
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15960364
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/960364 | Protein having nuclease activity, fusion proteins and uses thereof | Apr 22, 2018 | Issued |
Array
(
[id] => 15768803
[patent_doc_number] => 20200115419
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-16
[patent_title] => NEW OPTOGENETIC TOOL
[patent_app_type] => utility
[patent_app_number] => 16/603963
[patent_app_country] => US
[patent_app_date] => 2018-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15562
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16603963
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/603963 | NEW OPTOGENETIC TOOL | Apr 10, 2018 | Abandoned |
Array
(
[id] => 14019051
[patent_doc_number] => 20190071519
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-03-07
[patent_title] => METHODS FOR MAKING FULLY HUMAN BISPECIFIC ANTIBODIES USING A COMMON LIGHT CHAIN
[patent_app_type] => utility
[patent_app_number] => 15/951130
[patent_app_country] => US
[patent_app_date] => 2018-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37064
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15951130
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/951130 | METHODS FOR MAKING FULLY HUMAN BISPECIFIC ANTIBODIES USING A COMMON LIGHT CHAIN | Apr 10, 2018 | Abandoned |
Array
(
[id] => 15527793
[patent_doc_number] => 20200056202
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-20
[patent_title] => ANIMAL MODELS AND THERAPEUTIC MOLECULES
[patent_app_type] => utility
[patent_app_number] => 16/604120
[patent_app_country] => US
[patent_app_date] => 2018-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19415
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604120
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/604120 | ANIMAL MODELS AND THERAPEUTIC MOLECULES | Apr 9, 2018 | Pending |
Array
(
[id] => 13354685
[patent_doc_number] => 20180228882
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-16
[patent_title] => FUSION MOLECULE BASED ON TAA VARIANT
[patent_app_type] => utility
[patent_app_number] => 15/947469
[patent_app_country] => US
[patent_app_date] => 2018-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18957
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15947469
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/947469 | Fusion molecule based on TAA variant | Apr 5, 2018 | Issued |
Array
(
[id] => 14142055
[patent_doc_number] => 10251376
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-04-09
[patent_title] => Increasing healthy lifespan and delaying progression of age-related phenotypes by selectively removing senescent cells
[patent_app_type] => utility
[patent_app_number] => 15/943356
[patent_app_country] => US
[patent_app_date] => 2018-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 10
[patent_no_of_words] => 7486
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15943356
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/943356 | Increasing healthy lifespan and delaying progression of age-related phenotypes by selectively removing senescent cells | Apr 1, 2018 | Issued |
Array
(
[id] => 13554737
[patent_doc_number] => 20180328916
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-15
[patent_title] => BACILLUS THURINGIENSIS TOXIN RECEPTORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 15/940962
[patent_app_country] => US
[patent_app_date] => 2018-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10503
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 87
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15940962
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/940962 | None | Mar 28, 2018 | Issued |
Array
(
[id] => 13457993
[patent_doc_number] => 20180280539
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-10-04
[patent_title] => SYSTEMS AND METHODS FOR NUCLEIC ACID EXPRESSION IN VIVO
[patent_app_type] => utility
[patent_app_number] => 15/934587
[patent_app_country] => US
[patent_app_date] => 2018-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29381
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15934587
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/934587 | Systems and methods for nucleic acid expression in vivo | Mar 22, 2018 | Issued |
Array
(
[id] => 17378148
[patent_doc_number] => 11236145
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-01
[patent_title] => T cell receptors and immune therapy using the same against PRAME positive cancers
[patent_app_type] => utility
[patent_app_number] => 15/928785
[patent_app_country] => US
[patent_app_date] => 2018-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 21849
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15928785
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/928785 | T cell receptors and immune therapy using the same against PRAME positive cancers | Mar 21, 2018 | Issued |
Array
(
[id] => 16525310
[patent_doc_number] => 20200399390
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-24
[patent_title] => METHODS FOR PRODUCING LYMPHOCYTE PROGENITORS
[patent_app_type] => utility
[patent_app_number] => 16/492036
[patent_app_country] => US
[patent_app_date] => 2018-03-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15485
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16492036
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/492036 | METHODS FOR PRODUCING LYMPHOCYTE PROGENITORS | Mar 7, 2018 | Pending |